Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965454 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma Non-resectable, sponsored by Queen's Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04965454 is a Phase 2 study of Hepatocellular Carcinoma Non-resectable that is actively recruiting participants, run by Queen's Medical Center. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04965454, a Phase 2 study of Hepatocellular Carcinoma Non-resectable, is actively recruiting participants, sponsored by Queen's Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fluorine-18 fluorocholine
Study Locations (1)
Hawaii
- The Queen's Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965454
The ClinicalTrials.gov registry entry for NCT04965454 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma Non-resectable appearing as the primary indexed condition, and to 1 intervention - of which Fluorine-18 fluorocholine is the first listed.
NCT04965454 reports 1 study location spanning 1 distinct geographic area - top geographies include Hawaii.
Frequently Asked Questions
What is clinical trial NCT04965454 about?
NCT04965454 is a clinical study titled "Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma". This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is t...
What is the current status of trial NCT04965454?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-03-28. Estimated completion is 2028-06-30.
What conditions does trial NCT04965454 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma Non-resectable.
What interventions are being tested in trial NCT04965454?
The interventions under investigation include: Fluorine-18 fluorocholine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04965454?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04965454 being conducted?
This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma Non-resectable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.